DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $848,750 | +3.4% | 3,421 | 0.0% | 0.08% | +1.3% |
| Q2 2023 | $821,040 | -27.5% | 3,421 | -23.8% | 0.08% | -24.5% |
| Q1 2023 | $1,131,912 | -11.4% | 4,491 | -6.7% | 0.10% | -5.6% |
| Q4 2022 | $1,277,466 | +2.8% | 4,813 | 0.0% | 0.11% | -7.7% |
| Q3 2022 | $1,243,000 | +1.9% | 4,813 | 0.0% | 0.12% | +13.6% |
| Q2 2022 | $1,220,000 | -13.8% | 4,813 | -0.3% | 0.10% | -3.7% |
| Q1 2022 | $1,416,000 | -16.6% | 4,826 | -6.5% | 0.11% | -15.1% |
| Q4 2021 | $1,698,000 | -38.2% | 5,161 | -42.8% | 0.13% | -41.4% |
| Q3 2021 | $2,746,000 | +22.9% | 9,020 | +8.3% | 0.22% | +20.1% |
| Q2 2021 | $2,235,000 | +119.1% | 8,330 | +83.9% | 0.18% | +82.7% |
| Q1 2021 | $1,020,000 | +1.4% | 4,530 | 0.0% | 0.10% | -5.8% |
| Q4 2020 | $1,006,000 | +14.4% | 4,530 | +11.0% | 0.10% | +11.8% |
| Q3 2020 | $879,000 | +21.9% | 4,080 | 0.0% | 0.09% | +13.4% |
| Q2 2020 | $721,000 | +53.1% | 4,080 | +20.0% | 0.08% | +20.6% |
| Q1 2020 | $471,000 | -9.8% | 3,400 | 0.0% | 0.07% | +19.3% |
| Q4 2019 | $522,000 | +20.6% | 3,400 | +13.3% | 0.06% | +14.0% |
| Q3 2019 | $433,000 | +0.9% | 3,000 | 0.0% | 0.05% | -3.8% |
| Q2 2019 | $429,000 | +8.3% | 3,000 | 0.0% | 0.05% | +2.0% |
| Q1 2019 | $396,000 | +28.2% | 3,000 | 0.0% | 0.05% | +18.6% |
| Q4 2018 | $309,000 | -5.2% | 3,000 | 0.0% | 0.04% | +2.4% |
| Q3 2018 | $326,000 | +10.1% | 3,000 | 0.0% | 0.04% | 0.0% |
| Q2 2018 | $296,000 | +0.7% | 3,000 | 0.0% | 0.04% | -6.7% |
| Q1 2018 | $294,000 | +5.8% | 3,000 | 0.0% | 0.04% | +7.1% |
| Q4 2017 | $278,000 | +8.2% | 3,000 | 0.0% | 0.04% | +10.5% |
| Q3 2017 | $257,000 | +1.6% | 3,000 | 0.0% | 0.04% | +2.7% |
| Q2 2017 | $253,000 | -1.6% | 3,000 | 0.0% | 0.04% | -11.9% |
| Q1 2017 | $257,000 | +9.8% | 3,000 | 0.0% | 0.04% | +7.7% |
| Q4 2016 | $234,000 | -9.7% | 3,000 | -9.1% | 0.04% | -17.0% |
| Q3 2016 | $259,000 | -28.8% | 3,300 | -8.3% | 0.05% | -33.8% |
| Q2 2016 | $364,000 | +1.1% | 3,600 | -5.3% | 0.07% | -9.0% |
| Q1 2016 | $360,000 | +10.8% | 3,800 | +8.6% | 0.08% | +41.8% |
| Q4 2015 | $325,000 | +9.1% | 3,500 | 0.0% | 0.06% | -1.8% |
| Q3 2015 | $298,000 | -0.7% | 3,500 | 0.0% | 0.06% | +19.1% |
| Q2 2015 | $300,000 | +1.0% | 3,500 | 0.0% | 0.05% | -4.1% |
| Q1 2015 | $297,000 | -3.9% | 3,500 | -2.8% | 0.05% | -9.3% |
| Q4 2014 | $309,000 | +12.8% | 3,600 | 0.0% | 0.05% | +8.0% |
| Q3 2014 | $274,000 | -3.2% | 3,600 | 0.0% | 0.05% | -5.7% |
| Q2 2014 | $283,000 | +17.9% | 3,600 | +12.5% | 0.05% | +6.0% |
| Q1 2014 | $240,000 | -2.8% | 3,200 | 0.0% | 0.05% | 0.0% |
| Q4 2013 | $247,000 | +11.3% | 3,200 | 0.0% | 0.05% | +11.1% |
| Q3 2013 | $222,000 | +29.8% | 3,200 | +18.5% | 0.04% | +9.8% |
| Q2 2013 | $171,000 | – | 2,700 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |